|
|
 |
 |
104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft 2006
Abstract
Abstract
SA.01.07 Immediate morphological and functional effects of an anti-VEGF-therapy with intravitreal ranibizumab (Lucentis®) in patients with choroidal neovascularizations secondary to age-related macular degeneration Bolz M., Ahlers C., Hirn C., Simader C., Georgopoulos M., Lackner-Funovits B., Michels S., Schmidt-Erfurth U.
Department of Ophthalmology, Medical University Vienna Objective: Anti-VEGF-therapies show characteristic effects on the retinal morphology and function typically found in the first 3 months. As the optical coherence tomography (OCT) and the fluorescein angiography (FLA) gained in importance in follow-up examinations during therapy, in this study, outcomes of both examination techniques were correlated with the change in best corrected visual acuity (BCVA).
Methods: 30 patients with choroidal neovascularisations (CNV) secondary to age-related macular degeneration (AMD) received monthly intravitreal injections with 0.3mg or 0.5mg Ranibizumab (Lucentis®). OCT (OCT 3) examinations were performed on day 0, 8, 30, 60 and 90, FLA (HRA 2) examinations on day 0 and 90. Results were evaluated regarding lesion classification, therapeutically induced morphological retinal and pigmentepithelial changes and correlated with changes in BCVA (ETDRS).
Results: Intravitreal Ranibizumab caused a decrease in central retinal thickness assessed with OCT within 1 week in both dosis regimen. An increase in BCVA was found in less then 50% at this point in time, it was greatest at month 3. At month 3 intra- and subretinal exsudates could not found in OCT, whereas in FLA staining suggested a lesion persistency. The resorption of pigment epithelial detachments (PEDs) lasted longer and was dependent on PED height. There was a high correlation between the decrease in central retinal thickness (OCT) and vascular lekage (FLA) and the ensuing increase in BCVA.
Conclusions: Intravitreal Ranibizumab is an effective therapy targeting CNV secondary to AMD. A therapeutical effect on retinal morphology can already be observed after 1 week. Especially during the first 3 months there was a strong correlation between the decrease in central retinal thickness (OCT) and the increase in BCVA.
Zurück | Back
|
